Todd C. Davis

CIK: 0001392029

Transaction Breakdown

Open Market Buys (P)5 (15.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)14 (43.8%)

Compensation grants

Other (G, F, J, C, D, …)13 (40.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

LGND

LIGAND PHARMACEUTICALS INC

DirectorOfficer

PTHS

Pelthos Therapeutics Inc.

Director

PVLA

PALVELLA THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (32 total)

LGND
LIGAND PHARMACEUTICALS INC
Jun 30, 2026
Other(J)
Direct
132 shares at avg. $160.71$21K
PTHS
Pelthos Therapeutics Inc.
Jun 11, 2026
Purchase(P)
Direct
503 shares at avg. $28.73$14K
PTHS
Pelthos Therapeutics Inc.
Jun 11, 2026
Purchase(P)
Direct
35.4K shares at avg. $27.80$986K
PVLA
PALVELLA THERAPEUTICS, INC.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
3K shares-
LGND
LIGAND PHARMACEUTICALS INC
Mar 2, 2026
Award(A)
Direct
10.5K shares-
LGND
LIGAND PHARMACEUTICALS INC
Feb 15, 2026
Tax Payment(F)
Direct
4.3K shares at avg. $183.83$782K
LGND
LIGAND PHARMACEUTICALS INC
Feb 15, 2026
Tax Payment(F)
Direct
2.8K shares at avg. $183.83$516K
LGND
LIGAND PHARMACEUTICALS INC
Feb 15, 2026
Tax Payment(F)
Direct
2K shares at avg. $183.83$375K
LGND
LIGAND PHARMACEUTICALS INC
Feb 14, 2026
Tax Payment(F)
Direct
8.2K shares at avg. $183.83$1.5M
LGND
LIGAND PHARMACEUTICALS INC
Feb 14, 2026
Tax Payment(F)
Direct
15.6K shares at avg. $183.83$2.9M
LGND
LIGAND PHARMACEUTICALS INC
Feb 14, 2026
Award(A)
Direct
20.8K shares-
LGND
LIGAND PHARMACEUTICALS INC
Feb 14, 2026
Award(A)
Direct
39.6K shares-
LGND
LIGAND PHARMACEUTICALS INC
Dec 4, 2025
Gift(G)
Direct
130 shares-
PTHS
Pelthos Therapeutics Inc.
Jul 2, 2025
Award(A)
Direct
19.1K shares-
PTHS
Pelthos Therapeutics Inc.
Jul 2, 2025
Award(A)
Stock Option
Direct
58.2K shares-
PTHS
Pelthos Therapeutics Inc.
Jul 2, 2025
Award(A)
Restricted Stock Units
Direct
19.1K shares-
PTHS
Pelthos Therapeutics Inc.
Jul 1, 2025
Conversion(C)
Indirect
1.5M shares at avg. $10.00$15.0M
PTHS
Pelthos Therapeutics Inc.
Jul 1, 2025
Other(J)
Series A Convertible Preferred Stock
Indirect
31.3K shares-
LGND
LIGAND PHARMACEUTICALS INC
Jun 30, 2025
Other(J)
Direct
233 shares at avg. $91.08$21K
PVLA
PALVELLA THERAPEUTICS, INC.
Jun 10, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
12.4K shares-
LGND
LIGAND PHARMACEUTICALS INC
May 9, 2025
Purchase(P)
Direct
5.5K shares at avg. $105.67$584K
LGND
LIGAND PHARMACEUTICALS INC
May 9, 2025
Purchase(P)
Direct
2.3K shares at avg. $104.53$241K
LGND
LIGAND PHARMACEUTICALS INC
May 9, 2025
Purchase(P)
Direct
1.7K shares at avg. $104.57$176K
LGND
LIGAND PHARMACEUTICALS INC
Mar 4, 2025
Award(A)
Direct
21.4K shares-
LGND
LIGAND PHARMACEUTICALS INC
Feb 15, 2025
Tax Payment(F)
Direct
4.3K shares at avg. $120.00$511K

		Type	Shares	Price		Ownership
Jun 30, 2026	LGND LIGAND PHARMACEUTICALS INC	Other(J)	132	$160.71	$21,214	Direct
Jun 11, 2026	PTHS Pelthos Therapeutics Inc.	Purchase(P)	503	$28.73	$14,449	Direct
Jun 11, 2026	PTHS Pelthos Therapeutics Inc.	Purchase(P)	35,445	$27.80	$985,534	Direct
Jun 10, 2026	PVLA PALVELLA THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	3,000	-	-	Direct
Mar 2, 2026	LGND LIGAND PHARMACEUTICALS INC	Award(A)	10,495	-	$0	Direct
Feb 15, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	4,255	$183.83	$782,197	Direct
Feb 15, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	2,805	$183.83	$515,643	Direct
Feb 15, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	2,039	$183.83	$374,829	Direct
Feb 14, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	8,178	$183.83	$1,503,362	Direct
Feb 14, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	15,600	$183.83	$2,867,748	Direct
Feb 14, 2026	LGND LIGAND PHARMACEUTICALS INC	Award(A)	20,782	-	$0	Direct
Feb 14, 2026	LGND LIGAND PHARMACEUTICALS INC	Award(A)	39,644	-	$0	Direct
Dec 4, 2025	LGND LIGAND PHARMACEUTICALS INC	Gift(G)	130	-	-	Direct
Jul 2, 2025	PTHS Pelthos Therapeutics Inc.	Award(A)	19,108	-	$0	Direct
Jul 2, 2025	PTHS Pelthos Therapeutics Inc.	Award(A) Stock Option	58,230	-	-	Direct
Jul 2, 2025	PTHS Pelthos Therapeutics Inc.	Award(A) Restricted Stock Units	19,108	-	-	Direct
Jul 1, 2025	PTHS Pelthos Therapeutics Inc.	Conversion(C)	1,500,000	$10.00	$15,000,000	Indirect
Jul 1, 2025	PTHS Pelthos Therapeutics Inc.	Other(J) Series A Convertible Preferred Stock	31,279	-	-	Indirect
Jun 30, 2025	LGND LIGAND PHARMACEUTICALS INC	Other(J)	233	$91.08	$21,221	Direct
Jun 10, 2025	PVLA PALVELLA THERAPEUTICS, INC.	Award(A) Non-Qualified Stock Option (right to buy)	12,350	-	-	Direct
May 9, 2025	LGND LIGAND PHARMACEUTICALS INC	Purchase(P)	5,523	$105.67	$583,629	Direct
May 9, 2025	LGND LIGAND PHARMACEUTICALS INC	Purchase(P)	2,307	$104.53	$241,150	Direct
May 9, 2025	LGND LIGAND PHARMACEUTICALS INC	Purchase(P)	1,680	$104.57	$175,678	Direct
Mar 4, 2025	LGND LIGAND PHARMACEUTICALS INC	Award(A)	21,382	-	-	Direct
Feb 15, 2025	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	4,255	$120.00	$510,600	Direct

1-25 of 32 transactions

About Davis Todd C

Davis Todd C (SEC CIK 0001392029) files insider reports with the SEC as Chief Executive Officer of LIGAND PHARMACEUTICALS INC (LGND), Director of Pelthos Therapeutics Inc. (PTHS) and Director of PALVELLA THERAPEUTICS, INC. (PVLA).

Signal8 holds 17 ownership filings by Davis Todd C (1 Form 3, 16 Form 4), filed between Nov 15, 2024 and Jul 6, 2026. Those filings report 32 transactions, from Jun 14, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Davis Todd C's filings is in JUPITER, FL.

Recent filings by Davis Todd C

Jun 30, 2026: Other transaction of LGND shares (Form 4, code J).
Jun 11, 2026: Open-market purchases of PTHS shares (2 lines, Form 4, code P).
Jun 10, 2026: Grant or award of PVLA derivative securities (Form 4, code A).
Mar 2, 2026: Grant or award of LGND shares (Form 4, code A).
Feb 15, 2026: Tax withholdings of LGND shares (3 lines, Form 4, code F).

Other insiders filing for LIGAND PHARMACEUTICALS INC (LGND)

Reardon Andrew, CLO & Secretary
Zimmermann Martine, Director
Espinoza Octavio, Chief Financial Officer
Haas Jason, Director
Sabba Stephen L, Director
Aryeh Jason, Director

How to read Form 4 transaction codes